GlassScriptPhysician profile
Joseph P Kagan
NPI 1851388029
$18,741.17
in general payments reported to CMS, 2019-2025
59 companies · $3,268 in 2025
The $3,268 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $2,052 · 2021: $3,488 · 2022: $2,091 · 2023: $2,795 · 2024: $3,090 · 2025: $3,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,134 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,133.59 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,746.96 | 2019-2025 | |
| Abbvie INC. | $1,704.88 | 2021-2025 | |
| Novo Nordisk INC | $1,552.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,289.25 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,232.30 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $1,231.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $923.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $728.70 | 2019-2024 | Jardiance |
| Esperion Therapeutics, INC. | $664.85 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $612.80 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $531.19 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $522.44 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $515.34 | 2019-2022 | |
| Amarin Pharma, INC. | $417.80 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $364.18 | 2019-2024 | Xarelto |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $329.22 | 2019-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $316.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $279.49 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $237.37 | 2022 | |
| Sumitomo Pharma America, INC. | $228.35 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $219.71 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $209.14 | 2019-2024 | Trintellix |
| Paratek Pharmaceuticals, INC. | $206.87 | 2021-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $203.20 | 2019-2025 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $202.25 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $191.08 | 2023-2025 | |
| Allergan, INC. | $176.48 | 2019-2020 | |
| Abbott Laboratories | $168.20 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $151.69 | 2020-2022 | |
| Medtronic, INC. | $140.10 | 2023-2025 | Minimed 780g, Guardian Connect |
| Shield Therapeutics INC | $120.71 | 2023-2025 | Accrufer |
| Tolmar, INC. | $115.09 | 2025 | Jatenzo |
| Exact Sciences Corporation | $97.05 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $94.58 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $92.49 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $76.73 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $72.68 | 2019 | |
| Ardelyx, INC. | $72.63 | 2023-2024 | Ibsrela |
| Bausch Health US, LLC | $61.97 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $61.72 | 2024-2025 | Rexulti |
| Lucid Diagnostics INC. | $55.93 | 2024-2025 | |
| Verona Pharma, INC. | $53.34 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $52.40 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $46.32 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $42.30 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $38.91 | 2024-2025 | Watchman Flx |
| Astellas Pharma US INC | $38.32 | 2020 | |
| Nabriva Therapeutics, Plc | $30.12 | 2021 | |
| Circassia INC. | $27.82 | 2019-2020 | |
| Dynavax Technologies Corporation | $25.23 | 2019 | |
| Scilex Pharmaceuticals INC. | $23.75 | 2019 | |
| Cequr Corporation | $19.99 | 2025 | Cequr Simplicity |
| Indivior INC. | $19.27 | 2025 | Sublocade |
| Ibsa Pharma INC. | $18.59 | 2020 | |
| Pulmonx Corporation | $18.56 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Endo Pharmaceuticals INC. | $17.71 | 2019 | |
| Biogen, INC. | $16.54 | 2024 | Skyclarys |
| Life Molecular Imaging LTD | $16.43 | 2025 | Neuraceq |
| Covis Pharma Gmbh | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.